Finance

Lists
Q3 2026 earnings • released • EPS beat +39.80% • Revenue beat +1.14%
See results
TMCI:NASDAQ
Treace Medical Concepts, Inc
$4.03
-3.59%
(-0.15) 1D
$4.11
+1.99% (+0.080)
After hours
Closed: Nov 6, 4:00:00 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for TMCI...
Open
$3.95
High
$4.23
Low
$3.42
Mkt. cap
262.09M
Avg. vol.
217.45K
Volume
596.72K
52-wk high
$5.25
52-wk low
$1.17
EPS
-$0.93
Beta
1.59
Shares outstanding
65.04M
No. of employees
450
Open
$3.95
High
$4.23
Low
$3.42
Mkt. cap
262.09M
Avg. vol.
217.45K
Volume
596.72K
52-wk high
$5.25
52-wk low
$1.17
EPS
-$0.93
Beta
1.59
Shares outstanding
65.04M
No. of employees
450
News stories
From web sources and news partners
Profile
Treace Medical Concepts, Inc. is a medical device company, headquartered in Ponte Vedra Beach, Florida, specializing in the design, manufacture, and marketing of foot and ankle surgical devices and biologics. Lapiplasty, Treace’s novel primary surgical product, advanced the treatment of bunions, surgically correcting the metatarsal bone, for the first time, in all three dimensions. In March 2021, Treace announced its intent to launch an initial public offering. Trading on the Nasdaq under the ticker symbol “TMCI”, Treace opened its IPO in April 2021. Wikipedia
About Treace Medical Concepts, Inc
CEO-
Employees450
Founded2014
Headquarters-
SectorHealth Care
IndustryMedical device
Websitetreace.com
Analyst ratings
Based on 3 analysts giving stock ratings to TMCI in the past 3 months
Buy
Buy
1
Hold
2
Sell
0
12-month forecast
Based on 3 Wall Street analysts offering 12 month price targets for TMCI in the last 3 months.
Highest
Current $4.03
$7.00 (+73.70%)
Average
$5.50 (+36.48%)
Lowest
$4.50 (+11.66%)
Analyst
Recommendation
Action
Price target
Projected
Date
Rick Wise
Stifel Nicolaus
Hold
Maintained
$4.50
+11.7%
08/11/2026
Ben Haynor
Lake Street
Buy
Reiterated
$7.00
+73.7%
08/10/2026
Richard Newitter
Truist Financial
Hold
Reiterated
$5.00
+24.1%
08/10/2026
Danielle Antalffy
UBS
Hold
Maintained
$2.25
-44.2%
03/02/2026
Last report
Nov 6, 2026
Fiscal period
Q3 2026
-$0.15 / -$0.25
+39.80%beat
Revenue / Est. (USD)
48.25M / 47.71M
+1.14%beat
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
50.21M
62.52M
47.20M
45.38M
Cost of goods sold
10.51M
12.12M
9.79M
9.77M
Cost of revenue
10.51M
12.12M
9.79M
9.77M
Research and development expenses
4.68M
4.54M
4.62M
4.38M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
49.70M
51.78M
49.95M
46.19M
Operating expense
54.38M
56.32M
54.57M
50.56M
Total operating expenses
64.89M
68.44M
64.36M
60.33M
Operating income
-14.68M
-5.92M
-17.17M
-14.96M
Other non operating income
92.00K
88.00K
275.00K
202.00K
EBT including unusual items
-16.29M
-9.39M
-17.96M
-15.87M
EBT excluding unusual items
-15.29M
-6.66M
-17.96M
-15.87M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-16.29M
-9.39M
-17.96M
-15.87M
Net profit margin
-32.44%
-15.03%
-38.05%
-34.98%
Earnings per share
-0.22
-0.08
-0.12
-0.20
Interest and investment income
634.00K
527.00K
501.00K
445.00K
Interest expense
-1.34M
-1.35M
-1.57M
-1.56M
Net interest expenses
-704.00K
-823.00K
-1.07M
-1.12M
Depreciation and amortization charges
-
-
-
-
EBITDA
-11.90M
-4.11M
-16.27M
-13.07M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps